-+ 0.00%
-+ 0.00%
-+ 0.00%

On November 4, Boehringer Ingelheim and China Biopharmaceutical Co., Ltd. announced that they have reached a strategic multi-project option and licensing agreement to advance a potential next-generation cancer treatment plan based on antibody-conjugated drugs and T-cell connector technology.

Zhitongcaijing·11/04/2026 09:01:09
Listen to the news
On November 4, Boehringer Ingelheim and China Biopharmaceutical Co., Ltd. announced that they have reached a strategic multi-project option and licensing agreement to advance a potential next-generation cancer treatment plan based on antibody-conjugated drugs and T-cell connector technology.